Luteolin (CAS 491-70-3)

这就是贵公司的产品在自己欧洲网店里的样子
页面、名称、CAS 号、技术信息 —— 都已经就位。
现在只差 3 样,全部与贵公司自己的资料有关。
我们已经做好 产品页面 · 英文名称 · CAS 号 · 技术数据 · 欧盟合规信息框架
纯度 分析对照品试剂 · 包装规格 20mg —— 这些我们已经从贵公司的公开目录整理出来了
需要贵公司提供,只有 3 样 1. 贵公司的商标(logo)
2. 公司名称与注册地址
3. 每种规格的价格
收到这四样之后会发生什么

现在这份安全数据表和产品标签上印的,是 MolGod 的名称和地址。 这是因为贵公司的资料我们还没有 —— 我们不会替贵公司编造。

收到之后,我们把它们全部换成贵公司的
安全数据表、产品标签、产品页面、报价单、发票 —— 从头到尾都是贵公司的品牌, 不会出现我们的名字。

贵公司拿到的是一个可以直接开始卖货的网店,不是一份演示文件。

这份欧盟安全数据表草案,免费下载。 不收费,也不需要留下任何联系方式 —— 我们只是想让贵公司先看清楚, 我们做出来的文件到底是什么样子。
它是工作草案,尚未经专业人员审核,请勿直接对外提供。
适用范围:仅限欧盟市场

我们编制的安全数据表依据的是欧盟法规—— (EC) No 1907/2006(REACH)附件 II 及 (EU) 2020/878。

中文版本是从欧盟版本翻译而来的,仅供参考。 它不是中国市场上具有法律效力的文件,不能用于在中国境内的 申报、备案、运输或流通。

中国市场的安全数据表须按 GB/T 16483GB/T 17519 另行编制, 这不在本次交付范围内。贵公司在中国境内的合规文件,仍由贵公司自行负责。

我们是做网店的公司,不是化工公司。
不买货、不存货、不发货、不碰贵公司的客户、不从货款抽成。 货、客户、价格、订单、收款、发货 —— 全部在贵公司手里。
← 返回贵公司的全部产品

Luteolin. CAS 491-70-3. 20mg.

⚠️ Note: This safety data sheet is provided in English; a localized version is being prepared.

Free, and generated automatically from the sources listed on this page. No person has reviewed it, and it describes the substance in general — not your material, your process or your intended market.

REACH 2020/878
v1 · 03.09.2026
Download Safety Data Sheet (PDF)CAS 491-70-3 · PDF · 151 KBWorking draft — not yet reviewed and approved.

Section 9 — physicochemical properties: 4 of 22 established.

We show what is established and name what is not. Classification and identity are complete on every card; section 9 is where public data is thin.

What is in the buyer pack

Everything your compliance officer will ask for, in one file.

  • The product page as PDF — the record as published, so what you forward matches what you read.
  • The safety data sheet at your entitlement level — sixteen sections in the order set by REACH Annex II, for this substance, in the language you select.
  • The CLP label artwork — generated from the same classification as the sheet, so the two cannot disagree.
  • The specification, and the certificate of analysis where batch data exists.
  • sources.txt — every citation with the date it was read.
  • An explicit list of what we could not establish — fields marked unavailable rather than filled with an estimate. This is the honest part of the document and we do not hide it in a footnote.

Your European buyer is going to forward this to somebody who was not on the call. The pack exists so that what they forward is complete, self-explanatory and traceable — rather than four attachments and a sentence beginning “I think this is everything”.

These switch the language of this page. Single substances. Mixtures on enquiry. One document, one language — additional languages are priced separately. Every version, including the Chinese one, is written to EU law — (EC) No 1907/2006 (REACH) Annex II and (EU) 2020/878 — and translated from it. The Chinese version is a reference translation, not a legally valid document for the Chinese market: an SDS for China must be compiled separately to GB/T 16483 and GB/T 17519.

Daten transkribiert aus regulatorischen Registern und Fachliteratur, unter Angabe von Quelle und Ausgabe. Sie ersetzen nicht das Sicherheitsdatenblatt des Lieferanten. Felder ohne hinterlegte Quelle sind als solche gekennzeichnet.

Chemische Übersicht: Luteolin
SummenformelC15H10O6[1]
Molekulargewicht286.24 g/mol[1]
LogP (Lipophilie)1.4[1]
IUPAC-Name2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one[1]
SMILESC1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O[1]
InChIKeyIQPNAANSBPBGFQ-UHFFFAOYSA-N[1]

Synonyme: luteolin · 491-70-3 · 3',4',5,7-Tetrahydroxyflavone · Digitoflavone · Luteolol

Datenquellen: PubChem (NLM/NIH)
Zuletzt aktualisiert: 2026-09-03

📚 Wissenschaftliche Referenzen (Chicago Author-Date) (1 Quellen)
  1. PubChem. National Center for Biotechnology Information (NIH/NLM), chemical compound database. dotyczy: Summenformel · Molekulargewicht · LogP (Lipophilie) · IUPAC-Name · SMILES · InChIKey

WISSENSCHAFTLICHE FORSCHUNG

[1]PubMed2026
Luo L, Huang F, Fang G et al.. (2026). "Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS-Induced Colitis by Regulating AMPK Signalling.". Cell proliferation. https://doi.org/10.1111/c
[2]PubMed2025
Hao X, Yuan S, Ning J et al.. (2025). "Luteolin improves precancerous conditions of the gastric mucosa by binding STAT3 and inhibiting LCN2 expression.". International journal of biological sciences.
[3]PubMed2025
Gu M, Pang Z. (2025). "Luteolin inhibits inflammation and M1 macrophage polarization in the treatment of Pseudomonas aeruginosa-induced acute pneumonia through suppressing EGFR/PI3K/AKT/NF-κB and EGFR
[4]PubMed2025
Ye Z, Yang S, Chen L et al.. (2025). "Luteolin alleviated calcium oxalate crystal induced kidney injury by inhibiting Nr4a1-mediated ferroptosis.". Phytomedicine : international journal of phytotherap
[5]PubMed2025
Cao Q, Ding S, Zheng X et al.. (2025). "Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer.". Phytomedicine : international journal of phytotherapy and phytopha
[6]PubMed2024
Zhu M, Sun Y, Su Y et al.. (2024). "Luteolin: A promising multifunctional natural flavonoid for human diseases.". Phytotherapy research : PTR. https://doi.org/10.1002/ptr.8217
[7]PubMed2024
Chai S, Yang Y, Wei L et al.. (2024). "Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling.". Phytomedicine : inter
[8]PubMed2024
Han Z, Batudeligen, Chen H et al.. (2024). "Luteolin attenuates CCl4-induced hepatic injury by inhibiting ferroptosis via SLC7A11.". BMC complementary medicine and therapies. https://doi.org/10.1186/s
📚 Wissenschaftliche Referenzen (Chicago Author-Date) 12 refs · 1 baz

MOLECULE Bibliografie pro CAS (live aus 13+ Datenbanken)

Quellen: db:pubmed (12)

  1. db:pubmed Luo L, Huang F, Fang G et al.. (2026). "Luteolin Inhibits NLRP3 Inflammasome Activation to Ameliorate DSS-Induced Colitis by Regulating AMPK Signalling.". Cell proliferation. https://doi.org/10.1111/cpr.70134
  2. db:pubmed Hao X, Yuan S, Ning J et al.. (2025). "Luteolin improves precancerous conditions of the gastric mucosa by binding STAT3 and inhibiting LCN2 expression.". International journal of biological sciences. https://doi.org/10.7150/ijbs.111636
  3. db:pubmed Gu M, Pang Z. (2025). "Luteolin inhibits inflammation and M1 macrophage polarization in the treatment of Pseudomonas aeruginosa-induced acute pneumonia through suppressing EGFR/PI3K/AKT/NF-κB and EGFR/ERK/AP-1 signaling pathways.". Phytomedicine : international journal of phytotherapy and phytopharmacology. https://doi.org/10.1016/j.phymed.2025.156663
  4. db:pubmed Ye Z, Yang S, Chen L et al.. (2025). "Luteolin alleviated calcium oxalate crystal induced kidney injury by inhibiting Nr4a1-mediated ferroptosis.". Phytomedicine : international journal of phytotherapy and phytopharmacology. https://doi.org/10.1016/j.phymed.2024.156302
  5. db:pubmed Cao Q, Ding S, Zheng X et al.. (2025). "Luteolin Induces GPX4-dependent Ferroptosis and Enhances Immune Activation in Colon Cancer.". Phytomedicine : international journal of phytotherapy and phytopharmacology. https://doi.org/10.1016/j.phymed.2025.157117
  6. db:pubmed Zhu M, Sun Y, Su Y et al.. (2024). "Luteolin: A promising multifunctional natural flavonoid for human diseases.". Phytotherapy research : PTR. https://doi.org/10.1002/ptr.8217
  7. db:pubmed Chai S, Yang Y, Wei L et al.. (2024). "Luteolin rescues postmenopausal osteoporosis elicited by OVX through alleviating osteoblast pyroptosis via activating PI3K-AKT signaling.". Phytomedicine : international journal of phytotherapy and phytopharmacology. https://doi.org/10.1016/j.phymed.2024.155516
  8. db:pubmed Han Z, Batudeligen, Chen H et al.. (2024). "Luteolin attenuates CCl4-induced hepatic injury by inhibiting ferroptosis via SLC7A11.". BMC complementary medicine and therapies. https://doi.org/10.1186/s12906-024-04486-2
  9. db:pubmed Zhang N, Chen P, Liang X et al.. (2024). "Luteolin targets the AGE-RAGE signaling to mitigate inflammation and ferroptosis in chronic atrophic gastritis.". Aging. https://doi.org/10.18632/aging.205969
  10. db:pubmed Li Y, Wang Y, Ding Y et al.. (2024). "A Double Network Composite Hydrogel with Self-Regulating Cu(2+)/Luteolin Release and Mechanical Modulation for Enhanced Wound Healing.". ACS nano. https://doi.org/10.1021/acsnano.4c04816
  11. db:pubmed Quan J, Xie D, Li Z et al.. (2024). "Luteolin alleviates airway remodeling in asthma by inhibiting the epithelial-mesenchymal transition via β-catenin regulation.". Phytomedicine : international journal of phytotherapy and phytopharmacology. https://doi.org/10.1016/j.phymed.2024.156090
  12. db:pubmed Yu X, Xu L, Su C et al.. (2024). "Luteolin Protects against Vascular Calcification by Modulating SIRT1/CXCR4 Signaling Pathway and Promoting Autophagy.". The AAPS journal. https://doi.org/10.1208/s12248-024-00982-y
Regulatorischer Status der Substanz
Diese Substanz unterliegt regulatorischen Anforderungen: Bewirtschaftung gefährlicher Abfälle (BDO-Register). Details im Abschnitt "Regulatorischer Status (REACH/ECHA/CLP)" und im SDS. Regulatorische Information — schränkt den Kauf in diesem Shop nicht ein.
🧪 Chemische Daten
CAS-Nummer
491-70-3
Summenformel
C15H10O6
Molmasse
286.24 g/mol
IUPAC-Name (EN)
2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
SMILES
C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O
InChIKey
IQPNAANSBPBGFQ-UHFFFAOYSA-N
🔍 Externe Identifikatoren
13 von 16 ID-Systemen81%
DatenbankIdentifikatorAktionen
CAS Registry Number491-70-3Öffnen →
PubChem CID5280445[1]Öffnen →
InChIKeyIQPNAANSBPBGFQ-UHFFFAOYSA-N[1]Öffnen →
SMILESC1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O[1]
EC Number207-741-0[2]Öffnen →
ChEMBLCHEMBL151[3]Öffnen →
DrugBankDB15584Öffnen →
KEGG CompoundC01514Öffnen →
HMDBHMDB0005800Öffnen →
ChemSpider4444102[4]Öffnen →
MeSH UID (NLM)D047311Öffnen →
UNII (FDA)KUX1ZNC9J2Öffnen →
WikiData QIDQ415011Öffnen →

Quellen: PubChem (NIH), Wikidata SPARQL, KEGG, ChEMBL (EBI), CompTox CTX (EPA).

📚 Wissenschaftliche Referenzen (Chicago Author-Date) (4 Quellen)
  1. PubChem. National Center for Biotechnology Information (NIH/NLM), chemical compound database. dotyczy: PubChem CID · InChIKey · SMILES
  2. ECHA. EC Inventory — EINECS, ELINCS, NLP and List Numbers assigned under REACH. Helsinki: European Chemicals Agency. dotyczy: EC Number
  3. ChEMBL. European Bioinformatics Institute (EMBL-EBI), bioactivity database. dotyczy: ChEMBL
  4. ChemSpider. Royal Society of Chemistry, chemical structure database. dotyczy: ChemSpider

Dalsza literatura

Publications topically related to this CAS. They are not the source of any value given on this card.

Bibliografie (erweitert) (5)

  1. ★★☆☆☆ CROSSREF 🔓 OFFEN ❓ nicht verifiziert Yao, Xiaotian, Zhou, Zhengxi. 2024. "Dietary intake of luteolin is negatively associated with all-cause and cardiovascular mortality in chronic kidney disease patients." BMC Public Health 24 (1). https://doi.org/10.1186/s12889-024-19458-x. Link [abgerufen: 2026-09-04] CC0 (metadata)
  2. ★★☆☆☆ CROSSREF 🔓 OFFEN ❓ nicht verifiziert Anonymous. 2023. "luteolin, n." Oxford English Dictionary. https://doi.org/10.1093/oed/1097474231. Link [abgerufen: 2026-09-04] CC0 (metadata)
  3. ★★☆☆☆ CROSSREF 🔓 OFFEN ❓ nicht verifiziert Theoharides, Theoharis C.. 2020. "Luteolin supplements: All that glitters is not gold." BioFactors 47 (2): 242-244. https://doi.org/10.1002/biof.1689. Link [abgerufen: 2026-09-04] CC0 (metadata)
  4. ★★☆☆☆ CROSSREF 🔓 OFFEN ❓ nicht verifiziert Anonymous. 2020. "Luteolin." Definitions. https://doi.org/10.32388/82m2wu. Link [abgerufen: 2026-09-04] CC0 (metadata)
  5. ★★☆☆☆ CROSSREF 🔓 OFFEN ❓ nicht verifiziert Song, Youngsun. 2019. "P1-30-03 - Comparative Analysis of Luteolin and Luteolin-7-O-Glucoside on anti-Atherogenesis in ApoE Knockout Mice with Hyperhomocysteinemia.". https://doi.org/10.26226/morressier.5d5e517ebedcf39b7663b585. Link [abgerufen: 2026-09-04] CC0 (metadata)

Why this page can be checked

Identity

CAS, EC and molecular formula, resolved across the identifier systems a buyer uses. The count of systems resolved is shown, so you can see how well characterised this substance is rather than assuming.

Data

Every physicochemical value carries the source it came from and the date that source was read. Open any of them.

Classification

Read against the harmonised entry where one exists, with the index number stated. Self-classification is shown separately and labelled.

Regulatory

Inventory, restriction, authorisation and candidate-list status, each stated individually. Where a status is not established, this page says so — it never says no restrictions apply.

Documentation

Which documents exist, at what review level, in which languages, and when each was issued.

Supplier

Who is selling this, and what they have published about themselves.

Nothing on this page is a certification. It is a record you can audit.

Two guarantees, both with their limits stated

The Gap Report Guarantee

If the available evidence cannot support a defensible document for your CAS number and product specification, we will not invent the missing values. You receive a documented gap report and choose: a refund, store credit, or the report on its own.

A visible gap is worth more than a plausible number, because the plausible number is the one that fails when somebody checks it.

The Re-issue Promise

If a signed card is rejected by an authority or by a customer’s compliance officer on one of the points we checked and reported as passed, we re-issue it corrected at no charge and credit the original fee.

This covers the checks we performed and named. It does not cover registration status, tonnage, or your role in the supply chain — those are not ours to hold, and a guarantee that pretended otherwise would be worth nothing.

Luteolin — CAS 491-70-3, purity 分析对照品试剂, 20mg. Listed by Beijing Tong Guang. Prepared from the supplier’s public catalogue; not verified against their internal data.

Daten von PubChemQuelle: PubChem (NIH) · ChEMBL